News

Shares of INmune Bio climbed after the biotech company said its trial for treatment of a certain prostate cancer met its targets. The stock was up 11%, to $2.83, but is still down 65% over the ...
INmune Bio Inc. (NASDAQ:INMB) saw its stock jump 28% on Monday after announcing that its Phase I/II trial evaluating INKmune™ ...
INmune Bio Inc. (NASDAQ: INMB) (the 'Company'), a clinical-stage immunology and inflammation company, is pleased to report ...
Investing.com -- INmune Bio Inc. (NASDAQ: INMB) stock surged 28% after the company announced its Phase I/II trial of INKmune™ in metastatic castration-resistant prostate cancer (mCRPC) met both ...
Boca Raton, Florida, July 31, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company”), a clinical-stage ...
INKmune® is a pharmaceutical-grade, replication-incompetent human tumor cell line which conjugates to resting NK cells and delivers multiple, essential priming signals to convert the cancer ...
INKmune™ is treating patients in an open label Phase I/II trial in metastatic castration-resistant prostate cancer in the US. About INmune Bio Inc. (INMB) ...
“INKmune™ can be given to men with mCRPC in an out-patient setting and so far has an exemplary safety profile,” said RJ Tesi, MD CEO of INmune. “Data from the low dose cohort has shown ...
INKmune™ is tumor agnostic; it can be used to treat many types of NK-resistant tumors including leukemia, lymphoma, myeloma, lung, ovarian, breast, renal and nasopharyngeal cancer.
INKmune™ is a patented, pharmaceutical-grade, replication-incompetent human tumor cell line which conjugates to resting NK cells and delivers multiple, essential priming signals, akin to ...